Back to 2026 Abstracts
10-Year Follow-up of Locoregional Recurrence in Single Surgeon Oncoplastic Surgery in the United States
Pascal He
*1, Tyra albert
1, Rucha Kadam
1, Abhishek Chatterjee
2, Sarah Persing
21Tufts University School of Medicine, Boston, MA; 2Department of Surgery, Tufts Medical Center, Boston, MA
Background:Single surgeon oncoplastic surgery (OPS) is the surgical management of breast cancer whereby a surgeon trained in both breast surgical oncology and plastic surgery performs both a partial mastectomy and immediate reconstruction. The single surgeon approach can offer advantages in consolidating care to decrease patient burden without compromising oncologic or aesthetic outcomes. There are limited studies that report long-term oncologic outcomes of OPS, and even fewer that report such outcomes in the single surgeon OPS approach in the United States. Locoregional recurrence rates reported in literature range from 10-22% for traditional breast conserving surgery (BCS).
Methods:A retrospective chart review was conducted of all patients at a single institution with primary early-stage breast cancers (stages 0-2) that underwent single-surgeon OPS between 2015-2021. The primary outcome was locoregional recurrence; secondary outcomes were disease-free survival and overall survival.
Results:A cohort of 79 patients was identified with a mean follow up time of 7.8 years. Mean age at time of surgery was 56, and mean tumor size was 1.79 cm. The locoregional recurrence rate was 3.8%. Additionally, 3.8% of patients developed distant metastases, and 1.3% of patients developed a new primary breast cancer in the ipsilateral breast. Five-year disease-free survival was 96% (95% CI: 88.6-98.7), and 5-year overall survival was 97.4% (95% CI: 90.1-99.3).
Conclusion:The locoregional recurrence rate of single-surgeon OPS is low at 3.8% compared to historical rates for traditional BCS for 10-22%.
Back to 2026 Abstracts
